Healthcare Services

Global Palmoplantar Pustulosis Market Analysis for 2026–2030 with Strategic Forecast Insights for Businesses

April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Palmoplantar Pustulosis Market During The Forecast Period 2026–2030?

The palmoplantar pustulosis market has experienced substantial growth in recent years. It is projected to increase from $2.09 billion in 2025 to $2.26 billion in 2026, at a compound annual growth rate (CAGR) of 7.8%. This market’s expansion in the past can be attributed to several factors, including restricted treatment options for chronic skin conditions, a reliance on corticosteroids and topical agents, delayed diagnosis of pustular psoriasis, inadequate patient awareness concerning disease management, and a healthcare delivery model centered around hospitals.

The market for palmoplantar pustulosis is projected to experience robust expansion in the coming years. By 2030, it is predicted to reach $3.03 billion, growing at a compound annual growth rate (CAGR) of 7.6%. This anticipated growth can be attributed to the advent of new biologics and systemic therapies, the rising adoption of targeted immunomodulators, the development of teledermatology and digital health platforms, the broader acceptance of home-based phototherapy, and the increasing presence of online and retail pharmacies. Key trends observed during this period include a greater uptake of biologic therapies, the expanding application of targeted immunomodulators, the wider availability of home-based phototherapy solutions, the integration of teledermatology for chronic skin conditions, and improved access to treatments via online pharmacies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22090&type=smp

Which Major Factors Are Driving The Expansion Of The Palmoplantar Pustulosis Market?

The palmoplantar pustulosis market is anticipated to expand due to the rising occurrence of skin disorders. These disorders are defined as ailments impacting the skin’s structure, its functions, or its visual state. The heightened incidence of skin disorders stems from environmental shifts, lifestyle choices, and inherited predispositions. Factors in the environment, including air pollution, severe weather conditions, and contact with detrimental chemicals, can provoke skin irritation, leading to ailments such as eczema or acne. Palmoplantar pustulosis itself is a persistent skin condition predominantly affecting the palms of the hands and soles of the feet, manifesting as pustules, redness, and scaling; however, it can be addressed with various treatments aimed at enhancing skin health and reducing discomfort. As an illustration, data from December 2023, reported by the National Institutes of Health (NIH), a U.S.-based organization operating as the U.S. government’s primary medical research agency, indicated that the worldwide prevalence of atopic dermatitis stood at 2.6%, impacting approximately 204 million people worldwide. Consequently, the rising frequency of skin disorders is a key driver for expansion in the palmoplantar pustulosis market.

What Market Segments Are Evaluated Within The Palmoplantar Pustulosis Market?

The palmoplantar pustulosis market covered in this report is segmented –

1) By Treatment Type: Topical Treatments, Systemic Treatments, Biologics, Phototherapy

2) By Distribution Channel: Online Pharmacies, Retail Pharmacies

3) By Application: Hospitals, Dermatology Clinics, Homecare Settings

Subsegments:

1) By Topical Treatments: Corticosteroids, Vitamin D Analogues, Calcineurin Inhibitors, Keratolytics

2) By Systemic Treatments: Retinoids, Immunosuppressants, Phosphodiesterase-4 (PDE4) Inhibitors, Corticosteroids

3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-17 (IL-17) Inhibitors, Interleukin-23 (IL-23) Inhibitors, Interleukin-12/23 (IL-12/23) Inhibitors

4) By Phototherapy: Narrowband UVB Therapy (NB-UVB), Psoralen plus Ultraviolet A (PUVA) Therapy, Excimer Laser Therapy, Targeted Phototherapy

What Trends Are Affecting The Expansion Of The Palmoplantar Pustulosis Market?

Leading companies active in the palmoplantar pustulosis market are concentrating on developing innovative treatments, such as monoclonal antibodies that target inflammatory pathways, to enhance patient outcomes. A monoclonal antibody (mAb) is a uniform antibody generated by a single B-cell clone, designed to target a specific antigen for either therapeutic or diagnostic purposes. For example, in August 2023, Kyowa Kirin Co., Ltd., a pharmaceutical company headquartered in Japan, obtained partial change approval for LUMICEF for palmoplantar pustulosis in Japan. LUMICEF represents a targeted therapy that inhibits IL-17, delivering prompt and prolonged relief for inflammatory conditions including psoriasis and palmoplantar pustulosis. Its aim is to decrease inflammation and improve the quality of life for patients living with these chronic diseases.

Who Are The Top Market Participants Influencing The Palmoplantar Pustulosis Market?

Major companies operating in the palmoplantar pustulosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis International AG, GlaxoSmithKline PLC (GSK), Amgen Inc., Chugai Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Kyowa Kirin Co. Ltd., Almirall S.A., MorphoSys AG, MoonLake Immunotherapeutics AG, Aristea Therapeutics Inc., AnaptysBio Inc., Kamari Pharma Ltd., Johnson & Johnson, AstraZeneca, Eli Lilly and Company, Bayer AG, Merck & Co. Inc., UCB S.A., Boehringer Ingelheim International GmbH, Arcutis Biotherapeutics, Affibody AB, LEO Pharma A/S, Galderma, Incyte Corporation, Takeda Pharmaceutical Company Ltd., Roivant Sciences

Read the full palmoplantar pustulosis market report here:

https://www.thebusinessresearchcompany.com/report/palmoplantar-pustulosis-global-market-report

Which Region Currently Holds The Largest Share Of The Palmoplantar Pustulosis Market?

North America was the largest region in the palmoplantar pustulosis market in 2025. The regions covered in the palmoplantar pustulosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Palmoplantar Pustulosis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22090&type=smp

Browse Through More Reports Similar to the Global Palmoplantar Pustulosis Market 2026, By The Business Research Company

Hypertrophic And Keloid Scar Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/hypertrophic-and-keloid-scar-treatment-global-market-report

Scar Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/scar-treatment-global-market-report

Rare Diseases Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795